Meeting
2022 ASCO Annual Meeting
Ovarian function suppression is not indispensable in patients with early breast cancer who are older than age 40.
Authors
Jianqiao Xian
Sun Yat-Sen University Cancer Center, Guangzhou, China
Jianqiao Xian , Kaiming Zhang , Ya Sun , Yan Wang , Xinhua Xie , Feng Ye , Xing Li , Jun Yin , Weidong Wei , Xiangsheng Xiao , Xiaoming Xie , Xi Wang , Jun Tang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 539)
DOI
10.1200/JCO.2022.40.16_suppl.539
Abstract #
539
Poster Bd #
311
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Disease-free survival (DFS) as a surrogate for overall survival (OS) in patients (pts) with HR+/HER2− early breast cancer (EBC): A correlation analysis.
First Author: Michael Untch
Poster
2021 ASCO Annual Meeting
Optima: Optimal personalised treatment of early breast cancer using multi-parameter analysis, an international randomized trial of tumor gene expression test-directed chemotherapy treatment in a largely node-positive population.
First Author: Rob C. Stein
Poster
2021 ASCO Annual Meeting
Final analysis of the PROMISE-GIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer.
First Author: Matteo Lambertini
Poster
2017 ASCO Annual Meeting
Anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.
First Author: Vivianne C. Tjan-Heijnen